Company Profile For Cell Therapeutics, Inc.

Cell Therapeutics, Inc. (Cell Therapeutics) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and effective ways to treat cancer. Cell Therapeutics is developing pixantrone (BBR 2778), a deoxyribonucleic acid (DNA) major groove binder with an aza-anthracenedione molecular structure, differentiating it from anthracycline chemotherapy agents. A new chemical compound for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, solid tumors, and immunological disorders, pixantrone is being developed to improve activity and safety in treating cancers treated with the anthracycline family of anti-cancer agents. It is developing OPAXIO (paclitaxel poliglumex), which was previously referred to as XYOTAX, for the treatment of non-small cell lung cancer (NSCLC), and ovarian cancer.

BRIEF: For the six months ended 30 June 2009, Cell Therapeutics Inc.'s revenues decreased 99% to $40K. Net loss appli. to Common decreased 64% to $40.5M. Revenues reflect the absence of revenue from product sales. Lower loss was offset by the absence of cost of product sold, lower selling, general & administrative expenses, the absence of loss on exchange of convertible notes and the presence of gain on sale of investment in joint venture.